Vaccine Hesitancy and Strategies to Improve Immunization Coverage: A Comprehensive Review for Public Health and Health Administration Professionals

 Vaccine Hesitancy and Strategies to Improve Immunization Coverage: A Comprehensive Review for Public Health and Health Administration Professionals

Authors: Dr. Shekhar and Team, Doctor's Forum For All 🏥⚖️

Disclaimer

This article is for educational purposes only. The information provided herein is intended to support learning and professional development among public health and health administration students, practitioners, and researchers. It does not constitute medical, legal, or professional advice. Readers should consult appropriate institutional guidelines, regulatory authorities, and current scientific literature for clinical or administrative decision-making. The authors and publisher disclaim any liability arising from the use of this material.

Abstract

Background: Global immunization coverage has plateaued since the COVID-19 pandemic, with 13.5 million zero-dose children in 2025 and measles outbreaks rising across 57 countries. Vaccine hesitancy is frequently blamed for these shortfalls, yet the evidence distinguishing hesitancy from access failure remains fragmented and poorly translated into policy.

Methods: We conducted a narrative synthesis of WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) 2025 data, systematic reviews and meta-analyses published between 2024 and 2025 on communication interventions, vaccine mandates, and trust-building, and the WHO SAGE 5C determinants model.

Results: Global DTP3 coverage reached 85% in 2025, with 90% receiving at least one DTP dose. Measles coverage stalled at 84% for MCV1 and 77% for MCV2, far below the 95% threshold for outbreak prevention. An estimated 13.5 million children remained zero-dose, with more than half living in fragile or conflict-affected settings. Parental HPV vaccine hesitancy pooled at 39.6% globally (95% CI: 31.4–47.8%). Interactive, in-person communication interventions showed the strongest evidence of effectiveness, with 11 of 25 effective interventions being both interactive and in-person. Mandates produced short-run increases in first-dose uptake but limited evidence of sustained coverage gains. Trust-building through community health workers demonstrated increases in vaccination intention from 41% to 83% following trained Champion sessions.

Conclusion: Vaccine hesitancy is real but is frequently conflated with access barriers. Effective strategies are context-specific, relationship-based, and prioritize trust over persuasion. Health leaders must disaggregate hesitancy from access failure, invest in interactive communication, and rebuild trust through community-embedded messengers. Mandates alone are insufficient without addressing underlying access and confidence gaps.

Keywords: vaccine hesitancy, immunization coverage, zero-dose children, public health communication, trust, measles, DTP3

Introduction

Global immunization is not failing. It is stalling. The distinction matters because the solutions are different. A system that is stalling can be restarted with better logistics and outreach. A system that is failing requires a complete overhaul of trust and infrastructure.

In 2025, 90% of infants worldwide received at least one dose of the diphtheria-tetanus-pertussis (DTP) vaccine. That translates to nearly 116 million children. Eighty-five percent completed the full three-dose series. These numbers seem impressive. They mask a harder truth. Measles coverage, the true sentinel of population immunity, has barely budged. Only 84% of children received their first measles-containing vaccine (MCV1) in 2025. Just 77% received their second dose (MCV2). The threshold for preventing outbreaks is 95%. Fifty-seven countries reported large measles outbreaks in 2025 alone.

The gap between DTP and measles coverage reveals something uncomfortable. Children who start vaccination often don't finish. An estimated 7.3 million infants received their first DTP dose but dropped out before their first measles vaccine. That's not hesitancy. That's a system losing contact with families after the first visit.

Meanwhile, 13.5 million children remained completely unvaccinated in 2025. These are the zero-dose children. More than half live in fragile or conflict-affected countries. In these settings, vaccination services are simply unavailable. Nigeria has the largest absolute number. Yemen and Sudan are falling further behind.

Yet the conversation among health leaders often defaults to hesitancy. The "anti-vaxxer" narrative dominates headlines and policy discussions. It's a convenient frame. It locates the problem in individual attitudes rather than systemic failures. But the evidence doesn't support that simplification.

Vaccine hesitancy is defined by the WHO SAGE Working Group as a delay in acceptance or refusal of vaccination despite availability of vaccination services. The key phrase is "despite availability." A mother who walks three hours to a closed clinic is not hesitant. A father who cannot afford the bus fare to a vaccination center is not hesitant. A family displaced by conflict and living in a camp without cold-chain infrastructure is not hesitant. They are excluded.

That said, hesitancy is a real and growing problem in specific contexts. Parental hesitancy for HPV vaccination pooled at 39.6% globally (95% CI: 31.4–47.8%). Regional variation is stark. Europe reports 25.2%. Africa reports 57.6%. In high-income countries, political commitment to immunization has wavered. Hesitancy has increased even as access has improved. Trust in institutions, not just vaccines, is the underlying variable.

What is missing from most public health discourse is a clear-eyed assessment of which interventions actually work, which don't, and why health leaders keep making the same mistakes. The 5C model—confidence, complacency, calculation, convenience, and collective responsibility—provides a framework for understanding determinants. But it's often reduced to a checkbox exercise rather than a diagnostic tool.

This review synthesizes current evidence to answer three questions. First, what does the 2025 coverage data actually tell us about hesitancy versus access? Second, which interventions have demonstrated effectiveness in improving uptake and reducing hesitancy? Third, what are health leaders systematically getting wrong in their communication and policy responses?

The stakes are not abstract. Measles is the most contagious vaccine-preventable disease. A 95% coverage threshold is not a bureaucratic target. It's the mathematical requirement for herd immunity. Every percentage point below that threshold translates into preventable hospitalizations and deaths. The 48 measles outbreaks in the United States in 2025, triple the number from the previous year, are a warning. They will not stay contained.

This article is written for health leaders, clinicians, and public health practitioners who make decisions about immunization programs. It argues that the dominant framing of vaccine hesitancy as an information deficit is both empirically unsupported and practically counterproductive. What works is slower, harder, and less headline-friendly. It requires investing in relationships rather than messaging, in access rather than persuasion, and in trust rather than compliance.

Methods and Materials

Study Design: This article is a narrative synthesis of publicly available data and peer-reviewed literature. It is not a systematic review and does not claim to be one. The objective was to integrate the most current coverage estimates with the strongest available evidence on intervention effectiveness and the determinants of vaccine hesitancy, with a specific focus on identifying gaps between evidence and policy practice.

Setting and Population: The scope is global, with emphasis on low- and middle-income countries where the burden of zero-dose children is concentrated. Data sources reflect populations of infants, children, adolescents, and caregivers as relevant to routine immunization programs.

Data Sources: The primary data sources were the WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) for 2025, released July 2026; systematic reviews and meta-analyses published in 2024–2025 evaluating communication interventions, stage-of-change tailored interventions, and vaccine mandates; the WHO SAGE 5C determinants model and its adaptations; and empirical studies on trust-building and community health worker interventions.

Variables and Measurements: Coverage outcomes were measured as percentage of surviving infants receiving specified vaccine doses (DTP1, DTP3, MCV1, MCV2, HPV). Hesitancy was measured using pooled prevalence estimates from meta-analyses. Intervention effectiveness was assessed through reported effect sizes, including standard mean differences (SMD), risk ratios, and pre-post changes in vaccination intention.

Statistical Analysis: Where meta-analytic data were available, pooled estimates with 95% confidence intervals were reported as published. No primary statistical analysis was conducted for this synthesis.

Ethical Considerations: This article uses only publicly available, de-identified aggregate data and published literature. No primary data collection involving human subjects was conducted. Institutional review board approval was not required.

Results

Descriptive Data: Global Coverage in 2025

Global DTP3 coverage reached 85% in 2025. That means 110 million infants completed the three-dose series. DTP1 coverage was 90%, representing nearly 116 million infants. Both indicators improved by one percentage point from 2024. Coverage remains below pre-pandemic levels and has largely stagnated over the past decade.

Measles coverage tells a more concerning story. MCV1 coverage stood at 84%. MCV2 coverage was 77%. These are far below the 95% threshold required to prevent outbreaks. In 2025, 57 countries reported large measles outbreaks. The number of countries with very high MCV1 coverage (≥90%) fell from 98 in 2024 to 96 in 2025. Fourteen countries had coverage below 60%.

An estimated 13.5 million children were zero-dose in 2025. That represents a reduction of approximately 750,000 from 2024. It is still more than double the Immunization Agenda 2030 target of 6.4 million. More than half of zero-dose children lived in fragile or conflict-affected countries. India reduced its zero-dose population from 909,000 in 2024 to 679,000 in 2025. For the first time, India was no longer among the top 10 countries with the highest number of unvaccinated children against measles.

Dropout remains a critical issue. An estimated 7.3 million infants received DTP1 but did not proceed to MCV1. This dropout is concentrated in countries experiencing conflict, instability, and migration. Reaching children after the first contact is exceptionally difficult in these settings.

Hesitancy Prevalence

The pooled global prevalence of parental HPV vaccine hesitancy was 39.6% (95% CI: 31.4–47.8%) across 23 studies from 13 countries. Regional variation was substantial. Europe reported 25.2%. Africa reported 57.6%. Socioeconomic factors, including employment status, education, and income, were significantly associated with hesitancy.

Intervention Effectiveness: Communication

A systematic review of communication interventions to reduce parental vaccine hesitancy identified 3,873 articles. Thirty-three met inclusion criteria. Twenty-five of the 33 interventions showed effectiveness. Among the effective interventions, 11 were both in-person and interactive. Eleven were neither in-person nor interactive. Three were interactive but not in-person. Two were in-person but not interactive. The review concluded that communication interventions can reduce hesitancy and increase coverage. Interactive and in-person approaches showed the strongest supporting evidence from randomized controlled trials.

Intervention Effectiveness: Stage-of-Change Tailored Approaches

A meta-analysis of stage-of-change (SOC)-tailored interventions found a pooled standard mean difference of 0.54 (95% CI: 0.49–0.59, p < .001) for vaccination uptake. These interventions customize strategies based on an individual's readiness for behavioral change. Subgroup analyses showed effectiveness for older adults (SMD = 0.57, 95% CI: 0.22–0.92). They also showed effectiveness for parents or caregivers increasing children's vaccination (SMD = 0.53, 95% CI: 0.32–0.74). The evidence base was limited to five studies. The authors called for research in geographically diverse settings.

Intervention Effectiveness: Mandates

A scoping review of quasi-experimental evidence on COVID-19 vaccine mandates found that mandate announcements and implementations were associated with short-run increases in vaccination uptake. This was particularly true for first doses. Longer-run effects were estimated in only four studies. Two found null impacts over that horizon. The evidence suggested that mandates shifted the timing of vaccination. They brought doses forward among people who would have vaccinated anyway. They provided mixed evidence on whether they increased final coverage. Evidence on downstream outcomes, including mental health and other vaccination decisions, remained scant.

Trust-Building and Community Health Workers

Training health workers and community influencers as "Vaccine Champions" increased community member intention to vaccinate from 41% (394/960) to 83% (822/991) before and after a session. The Be REAL framework—Relate, Explore, Assist, Leave the door open—was developed to prepare community health workers to prioritize relationship-building as a primary goal. Vaccine uptake is secondary to the quality of the relationship formed. This approach aims to foster true partnership between health workers and community members. It can increase trust in the broader public health system beyond adherence to a specific recommendation.

Determinants: The 5C Model and Its Limitations

The 5C model—confidence, complacency, calculation, convenience, and collective responsibility—has been widely applied to understand vaccine hesitancy. A systematic review of hesitancy toward non-COVID vaccines in South Asia found the model useful. It noted that the model does not include a "C" covering knowledge and awareness. Knowledge and awareness emerged as a main factor influencing hesitancy and refusal. The authors recommended that future research explore the newly introduced 7C and 8C models. These incorporate conspiracy theories and psychosocial motivations for seeking vaccination solely for certification purposes.

Discussion

Key Findings

Three findings stand out.

First, the dominant narrative of vaccine hesitancy as the primary barrier to coverage is empirically unsupported. The data show that dropout and access failure account for a larger share of unvaccinated children than refusal. More than half of zero-dose children live in conflict-affected settings where vaccination services are unavailable, not refused. The 7.3 million infants who start but do not complete vaccination are not hesitaters. They are children whose families lost contact with the health system.

Second, what works is interactive and relational. The systematic review of communication interventions found that 11 of 25 effective interventions were both in-person and interactive. The Vaccine Champions program increased vaccination intention from 41% to 83% through trained community messengers. The Be REAL framework explicitly prioritizes relationship over adherence. These findings converge on a single principle. Trust is built through conversation, not campaigns.

Third, mandates are not a solution to hesitancy. They produce short-run increases in first-dose uptake. The evidence for sustained coverage gains is mixed. Mandates address convenience by making vaccination the default. They do little to address confidence. In contexts where trust in institutions is already low, mandates risk hardening resistance.

Comparison with Prior Literature

These findings align with and extend previous reviews. The Cochrane review by Oyo-Ita et al. found that face-to-face interventions and reminder systems improve coverage, particularly in low- and middle-income countries. The 2015 SAGE Working Group review by Jarrett et al. identified dialogue-based approaches as more effective than information-only campaigns. The current synthesis adds urgency by demonstrating that the gap between evidence and practice has not narrowed in the intervening decade.

The finding that more than half of zero-dose children live in fragile settings is consistent with WHO's Immunization Agenda 2030 framing. That framework emphasizes equity and reaching the hardest-to-reach populations. The concentration of zero-dose children in conflict zones is not a new finding. The persistence of this pattern despite global recovery efforts suggests that current strategies are insufficiently targeted.

Limitations

This synthesis has several limitations. It is not a systematic review. The literature selection was purposive and may have omitted relevant studies. The meta-analytic evidence on stage-of-change interventions was limited to five studies. The authors themselves noted the need for geographically diverse replication. The mandate evidence is concentrated in high-income countries. This raises questions about external validity to settings with different health systems and enforcement capacity. The relationship between trust and vaccination is bidirectional and difficult to disentangle. Trust in health systems may be both a cause and a consequence of vaccination experience. Finally, the coverage data are national estimates and may mask substantial subnational inequities.

Public Health Implications

The implications for policy and practice are direct.

First, health leaders must disaggregate hesitancy from access failure. They must stop using "vaccine hesitancy" as a catch-all explanation for low coverage. In settings where zero-dose children are concentrated in conflict zones, the primary intervention is access. This means mobile clinics, cold-chain logistics, and humanitarian coordination. It is not persuasion. In settings where coverage has declined despite availability, hesitancy is a plausible driver. The intervention should be dialogue-based.

Second, health leaders must invest in interactive, in-person communication. The evidence favors conversations over campaigns. This means funding training for health workers and community health workers in motivational interviewing and relationship-building skills. The Be REAL framework and Vaccine Champions model provide replicable templates. Digital and remote interventions have a role. They are not substitutes for human connection.

Third, health leaders must rebuild trust before it is needed. Trust is not built during an outbreak. It is built through consistent, respectful engagement over time. Community health workers are the most credible messengers because they are embedded in the communities they serve. Investing in them is investing in the infrastructure of trust.

Fourth, policymakers must use mandates cautiously and only with strong access infrastructure. Mandates can raise coverage when vaccination is easy and exemptions are clear. Without those conditions, they risk polarization and resistance. Policymakers should evaluate mandates not on short-run uptake alone. They should assess downstream outcomes, including trust in health systems and future vaccination decisions.

Fifth, health leaders must address knowledge gaps without falling into the deficit trap. The 5C model's omission of knowledge and awareness is a practical limitation. People need accurate information. Information alone rarely changes behavior. Knowledge must be delivered in the context of relationship, respect, and relevance. School-based education and intergenerational conversations may be promising avenues.

Conclusion

This narrative synthesis examined global immunization coverage data from 2025, the prevalence and determinants of vaccine hesitancy, and the effectiveness of various interventions designed to improve uptake. The findings demonstrate that vaccine hesitancy, while real, is frequently conflated with access barriers in public health discourse and policy responses.

Global DTP3 coverage reached 85% in 2025, but measles coverage remained dangerously low at 84% for MCV1 and 77% for MCV2. These figures fall far short of the 95% threshold required for herd immunity. An estimated 13.5 million children remained zero-dose, with more than half living in fragile or conflict-affected settings where vaccination services are unavailable rather than refused. An additional 7.3 million infants started but did not complete their vaccination series, representing a failure of retention rather than a failure of acceptance.

Interactive, in-person communication interventions demonstrated the strongest evidence of effectiveness in reducing hesitancy and improving coverage. Trust-building through community health workers, exemplified by the Vaccine Champions program and the Be REAL framework, showed substantial increases in vaccination intention. Mandates produced short-run increases in first-dose uptake but limited evidence of sustained coverage gains, and they risk hardening resistance in contexts where institutional trust is already low.

The implications for public health policy and practice are clear. Health leaders must disaggregate hesitancy from access failure. They must invest in interactive, relationship-based communication. They must rebuild trust through community-embedded messengers. They must use mandates cautiously and evaluate them on downstream outcomes, not just short-run uptake. And they must address knowledge gaps without falling into the deficit trap that assumes information alone changes behavior.

Future work should focus on several areas. First, research is needed on the effectiveness of stage-of-change tailored interventions in geographically diverse settings, as the current evidence base is limited to five studies. Second, the relationship between trust in health systems and vaccination behavior requires longitudinal investigation to disentangle cause and effect. Third, subnational coverage data must be strengthened to identify and address inequities masked by national averages. Fourth, implementation research should examine how to scale interactive, in-person communication interventions in resource-constrained settings. Finally, the newly introduced 7C and 8C models of vaccine hesitancy determinants should be validated and applied in diverse populations.

Vaccines are the intervention. Vaccination is the outcome. The space between them is where public health succeeds or fails.

References

1. World Health Organization. Ten threats to global health in 2019. Geneva: WHO; 2019.

2. MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161–4164.

3. World Health Organization, United Nations Children's Fund. WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) 2025. Geneva: WHO; 2026.

4. Oyo-Ita A, Wiysonge CS, Oringanje C, et al. Interventions for improving coverage of childhood immunisation in low- and middle-income countries. Cochrane Database Syst Rev. 2023;1:CD008145.

5. Chen S, et al. Effectiveness of stage-of-change (SOC)-tailored interventions in increasing uptake of any type of vaccination: a systematic review and meta-analysis. Appl Psychol Health Well Being. 2025;17(2):e70022.

6. Jwa S, Imanishi Y, Ascher MT, Dudley MZ. Communication interventions to reduce parental vaccine hesitancy: a systematic review. Vaccine. 2025;61:127401.

7. Jarrett C, Wilson R, O'Leary M, Eckersberger E, Larson HJ; SAGE Working Group on Vaccine Hesitancy. Strategies for addressing vaccine hesitancy—a systematic review. Vaccine. 2015;33(34):4180–4190.

8. Dubé E, Gagnon D, MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Strategies intended to address vaccine hesitancy: review of published reviews. Vaccine. 2015;33(34):4191–4203.

9. Jamison AM, Brewer J, Hamlin MD, et al. The Be REAL Framework: enhancing relationship-building skills for community health workers. Health Promot Pract. 2024;25(6):939–944.

10. Training health workers and community influencers to be Vaccine Champions: a mixed-methods RE-AIM evaluation. BMJ Glob Health. 2024.

11. An open repository of COVID-19 vaccine mandate studies with a worked scoping review of quasi-experimental evidence. npj Vaccines. 2026;11:01454-4.

12. Factors influencing vaccine hesitancy toward non-COVID vaccines in South Asia: a systematic review. BMC Public Health. 2025;25:22462-4.

13. World Health Organization. Immunization Agenda 2030: a global strategy to leave no one behind. Geneva: WHO; 2020.

14. Lewandowsky S, Cook J, Ecker UKH, et al. The Debunking Handbook 2020. Canberra: Australian National University; 2020.

15. de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. Lancet. 2020;396(10255):898–908.

16. Betsch C, Schmid P, Heinemeier D, et al. Beyond confidence: development of a measure assessing the 5C psychological antecedents of vaccination. PLoS One. 2018;13(12):e0208601.

17. Thomson A, Robinson K, Vallée-Tourangeau G. The 5As: a practical taxonomy for the determinants of vaccine uptake. Vaccine. 2016;34(8):1018–1024.

18. Habersaat KB, Betsch C, Danchin M, et al. Ten considerations for effectively managing the COVID-19 transition. Nat Hum Behav. 2020;4(7):677–687.

19. World Health Organization. Behavioural and social drivers of vaccination: tools and practical guidance. Geneva: WHO; 2022.

20. UNICEF. The State of the World's Children 2023: For every child, vaccination. New York: UNICEF; 2023.